Company profile

Ticker
PVCT
Exchange
CEO
Bruce Horowitz
Employees
Incorporated in
Location
Fiscal year end
Former names
Provectus Pharmaceutical Inc, Provectus Pharmaceuticals Inc, SPM Group Inc, Zamage Digital Imaging Inc
SEC CIK
IRS number
900031917

PVCT stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

13 May 20
10 Jul 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue
Net income -1.83M -1.56M -1.82M -2.18M
Diluted EPS 0 -0.01 0 -0.01
Operating income -1.45M -1.22M -1.44M -1.84M
Net change in cash -376.97K 155.92K -889.44K -443.67K
Cash on hand 213.74K 590.71K 434.79K 1.32M
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Net income -6.92M -8.15M -13.52M -24.43M
Diluted EPS -0.02 -0.02 -0.04 -0.12
Operating income -6.3M -8.05M -13.32M -24.51M
Net change in cash 539.72K -54.52K -1.06M -13.01M
Cash on hand 590.71K 50.99K 105.5K 1.17M
Cost of revenue

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
25 Mar 19 Heather Raines Common Stock Grant Aquire A No 0 50,000 0 1,163,153
13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Competition
ICH
Management Discussion
  • Total operating expenses were $6,299,696 for the year ended December 31, 2019, a decrease of $1,754,529 or 21.8% compared to the year ended December 31, 2018. The decrease was driven primarily by our transformation and process improvement efforts within the Company. Net loss for the year ended December 31, 2019 was $6,922,537, a decrease of $1,230,518 or 15.1% which resulted from costs incurred in connection with our preclinical and clinical trial programs and general and administrative costs.
  • Research and development expenses were $4,002,014 for the year ended December 31, 2019, a decrease of $745,543 or 15.7% compared to the year ended December 31, 2018. The decrease was due to (i) lower clinical operations due to closure of Phase III study in 2019 and drug manufacturing in 2018, (ii) lower insurance costs, and (iii) lower payroll and related taxes due to a lower negotiated employment agreement.
  • General and administrative expenses were $2,297,682 for the year ended December 31, 2019, a decrease of $1,008,986 or 30.5% compared to the year ended December 31, 2018. The decrease was due to (i) lower legal fees as we concluded the Company’s lawsuits against former accounting vendors, (ii) lower payroll and related taxes, and (iii) lower professional fees, partially offset by (vi) increased director fees (from having period-over-period, a five-member Board compared to a four-member Board in previous year).
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Acad, addressed, adverse, adversely, affirmed, Aid, annum, assevere, ASU, attributable, autolytic, average, beginning, begun, Bruce, carryback, chain, clarification, compartment, confidence, constituted, contractual, COO, coordinated, correlated, CoV, criteria, declared, deduction, deferment, deferral, depository, Dev, directly, Disaster, disbursement, disrupt, disruption, driven, economic, EIDG, EIDL, eligibility, eligible, enactment, ensure, envisioned, evolve, experienced, experiencing, facility, Fahrenbacher, forgivable, full, functional, functioning, gene, global, Gocheva, guidance, health, heightened, holder, Horowitz, ICD, Immunol, induction, ineligible, ingredient, inhibition, Injury, insufficient, interpreted, invasive, judgement, launched, legislation, lending, liver, long, minimize, mNET, monthly, multiple, mUM, myeloid, Nishimura, Occupancy, Oncol, Oral, outbreak, pandemic, Paycheck, permission, Piao, PPP, precautionary, President, progression, prolonged, qualified, qualifying, rate, RB, Recently, refundable, regaining, relief, rely, reportedly, respiratory, Sci, service, side, signaling, sixty, Snyder, social, spread, strain, superficial, Supreme, syndrome, tax, technical, temporary, trading, transformation, Trump, type, uncertain, unforgiven, vaccine, varying, visceral, widespread, World, worldwide
Removed: advisory, agreed, answer, approach, arising, attorney, balance, BHS, Bible, candidate, comparability, comparative, confidential, conform, counsel, denying, disgorgement, enabling, examination, exclusive, expertise, forensic, forthcoming, found, group, hearing, instructed, July, labor, LLP, matter, measure, modified, offset, oncolytic, partially, payment, PC, practical, prejudgment, prior, prominent, reclassified, recognition, recognize, recover, remained, requiring, resolved, retained, retrospective, ROU, RSM, shareholder, Smith, transparency, uncertainty, unchanged, unsubstantiated, vi, xanthene